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Abstract
The lamin A/C (LMNA), nuclear intermediate filament proteins, is a basic component of the nuclear lamina. Mutations in
LMNA are associated with a broad range of laminopathies, congenital diseases affecting tissue regeneration and
homeostasis. Heart tissue specific transgenic mice of human LMNA E82K, a mutation causing dilated cardiomyopathy, were
generated. Lmna
E82K transgenic mouse lines exhibited thin-walled, dilated left and right ventricles, a progressive decrease of
contractile function assessed by echocardiography. Abnormalities of the conduction system, myocytes disarray, collagen
accumulation and increased levels of B-type natriuretic peptide (BNP), procollagen type III a1 (Col3a1) and skeletal muscle
actin a1 (Acta1) were detected in the hearts of Lmna
E82K transgenic mice. The LMNA E82K mutation caused mislocation of
LMNA in the nucleus and swollen mitochondria with loss of critae, together with the loss of nuclear envelope integrity. Most
interestingly, we found that the level of apoptosis was 8.5-fold higher in the Lmna
E82K transgenic mice than that of non-
transgenic (NTG) mice. In the presence of the LMNA E82K, both of FAS and mitochondrial pathways of apoptosis were
activated consistent with the increase of FAS expression, the release of cytochrome c from mitochondria to cytosol and
activation of caspase-8, -9 and -3. Our results suggested that the apoptosis, at least for the LMNA E82K or the mutations in
the rod region of Lamin A/C, might be an important mechanism causing continuous loss of myocytes and lead to
myocardial dysfunction. It could be a potential therapeutic means to suppress and/or prevent inappropriate cardiac cell
death in patients carrying LMNA mutation.
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Introduction
The LMNA gene is alternatively spliced to produce the two
intermediate filament proteins termed nuclear lamin A/C, which
locate to the nuclear lamina, a fibrous structure underlying the
inner nuclear membrane [1]. Lamin A/C, emerin and complex
which links the nucleoskeleton and cytoskeleton (LINC) form a
variety of macro-protein complexes at the nuclear envelope and
together cross-link the nuclear skeleton to the cytoskeleton. These
protein complexes function to maintain nuclear architecture and
stability and cellular tensegrity [2–4]. The lamins play important
roles in DNA replication, chromatin organization, regulation of
gene expression, spatial organization of the nuclear pore and the
correct anchorage of the nuclear envelope proteins, cell develop-
ment, differentiation and apoptosis [5].
The mutations in the LMNA gene has been shown to cause at
least nine different autosomal recessive and dominant genetic
diseases, collectively called laminopathies [6,7]. More than 40
mutations in the LMNA gene have been shown to be involved in
the severity of the cardiac symptoms, characterized by conduction
defect, arrhythmias, left ventricular (LV) dysfunction, dilation with
heart failure or sudden death [8–13].
Lamin A/C plays a crucial role in many cellular activities, but it
is poorly understood why and how different mutants cause such
diverse phenotypes in specific tissues, but other tissues are
apparently unaffected [14], and the identification of the precise
molecular mechanisms of LMNA mutations leading to lamino-
pathies is also critical for developing new therapeutic strategies to
prevent cardiac dysfunction and sudden death.
A novel mutation E82K in lamin A/C gene has been found to
cause dilated cardiomyopathy (DCM) in a large Chinese pedigree
with 50 family members [15]. In the current paper, a heart tissue
specific transgenic mice expressing LMNA E82K was generated
and the mechanism causing dilated cardiomyopathy for this
mutation were investigated in the transgenic mice.
Results
Generation of the transgenic mice
C57BL/6J mice carrying the human LMNA E82K gene were
established (Fig. 1). Two lines of Lmna
E82K transgenic mice with
high level of expression were selected among 53 founders by
western blot analysis (Fig. 1C). The Lmna
E82K transgenic mice
were indistinguishable from their non-transgenic (NTG) litter-
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lines occurred from 3 months old and mortality was 15.8% (3 of
19 for founder 30) and 11.1% (2 of 18 for founder 35) at 10
months of age respectively, while no death was observed in NTG
mice.
Lmna
E82K caused dysfunction of heart in transgenic mice
Ventricular size and function of the two transgenic lines
were assessed using echocardiography. The parameters of
M-mode echocardiography from the NTG and Lmna
E82K
transgenic mice at 2, 4, 6 and 8 months of age were sum-
marized in Table 1 and Table S1. LMNA E82K mutation
significantly increased the heart to body weight ratio by 10%
(Fig. 2A, n=14, P,0.01) by gross morphology examination.
The representative M-mode echocardiograms from founder 35
at 6 months of age were shown in figure 2B. To sum up, the
LMNA E82K hearts exhibited thin-walled and dilated left and
right ventricles when compared with NTG hearts (Table 1).
Lmna
E82K transgenic mice developed a progressive LV dilation
and dysfunction associated with a progressive decrease of
contractile function, evidenced by decreased LV percent
fractional shortening (FS %) which exhibited a significance
from 2 months of age compared with NTG mice (Table 1 and
Table S1, P,0.01).
Electrocardiography (ECG) measurements were performed in
mutant and NTG mice at 7 months of age (Table 2). Compared
with WT mice, the PR interval and QRS complex duration had a
tendency of increase in both of the transgenic lines, but only the
mice generated from founder 35 showed a significant increase in
the QRS complex duration (P,0.05) in 7 mice with ECG
recording. Under light microscopy, myocyte disarray, interstitial
fibrosis were observed in the Lmna
E82K transgenic mice compared
with the NTG mice (Fig. 2C–E). The expression level of
hypertrophic markers, BNP, Acta1 and Col3a1, were obviously
increased in both of the two transgenic lines compared with the
NTG mice (Fig. 2F, the data from founder 35).
Morphological changes of myocytes and its nucleus in
the Lmna
E82K transgenic mice
The immunofluorescence staining of LMNA protein indicated
that LMNA E82K was mislocated in the transgenic heart instead
of nuclear rim localization in the NTG heart at 7 months of age
(Fig. 3A). Ultrastructural observation indicated that enlarged
mitochondria and sarcoplasmic reticulum, and loss of nuclear
envelope integrity due to the expression of LMNA E82K existed in
the Lmna
E82K mice compared with that of NTG mice (Fig. 3B
and C).
The FAS and mitochondrial pathways of apoptosis were
activated in Lmna
E82K transgenic mice
Apoptosis of myocytes was detected in In situ terminal dUTP
nick end-labeling (TUNEL) assay in heart tissue from Lmna
E82K
transgenic mice and NTG mice (Fig. 4A). The apoptotic index was
increased to 5.6762.94% in the transgenic mice while it was
0.6761.03% in the NTG mice (Fig. 4B, n=3,P,0.01). We found
that the expression of FAS was upregulated significantly in the
Lmna
E82K transgenic mice (Fig. 5A, n=3,P,0.05). The expression
of procaspase-8 and the activated caspase-8 were increased 84.8%
(Fig. 5A and B, n=3,P,0.01) and 32.4% (Fig. 5A and B, n=3,
P,0.05) respectively. Meanwhile, the expression of procaspase-3
and the activated caspase-3 were 4.4-fold and 10.4-fold higher in
the Lmna
E82K transgenic mice than that of NTG mice (Fig. 5A and
C, n=3,P,0.001) respectively. The expression of LMNA E82K
also caused the release of cytochrome c from mitochondria to
cytosol, and results showed that 47% of cytochrome c in cytosolic
concentrations were accompanied by decreased mitochondrial
concentrations in the Lmna
E82K transgenic mice (Fig. 6A and B,
n=3, P,0.001). Meanwhile, the expression of procaspase-9 and
the activated caspase-9 were 2.9-fold and 13.5-fold higher in the
Lmna
E82K transgenic mice than that of NTG mice (Fig. 6A and C,
Figure 1. Generation of the transgenic mice. (A) The LMNA E82K
transgenic construct was generated by inserting the target genes under
the control of the a-MHC heart tissue specific promoter and the
transgenic mice were created following microinjection. (B) Screening of
mouse genomic DNA by PCR for the presence of LMNA E82K gene. M:
molecular weight marker. Lane 1: positive control of Lmna
E82K
transgenic mice; lane 2: negative control; lane 3: blank control; lane 5
and 6: positive Lmna
E82K transgenic mice; lane 4 and 7: negative
transgenic mice. (C) The mouse lines, founder 30 and 35, with over-
expression of LMNA E82K were selected by the western blot procedure
using GAPDH as normalization.
doi:10.1371/journal.pone.0015167.g001
Table 1. Echocardiographic characteristics of NTG and
Lmna
E82K transgenic mice at 6 months of age.
Parameters NTG
Lmna
E82K
(line 30)
Lmna
E82K
(line 35)
Number of mice 19 18 18
LVEDD, mm 3.9260.24 4.5960.29
# 4.4160.23
#
LVESD, mm 2.7160.28 3.5760.47
# 3.4960.26
#
LVEDV, mL 67.0869.60 97.34614.68
# 88.74611.30
#
LVESV, mL 27.9767.02 55.05617.28
# 51.0369.26
#
LVPWD, mm 0.6660.09 0.5660.10
{ 0.5660.06
{
LVPWS, mm 0.9160.09 0.7260.12
# 0.7160.07
#
LVAWD, mm 0.7460.07 0.6860.08 0.6160.06
#
LVAWS, mm 0.9460.12 0.8360.13* 0.7760.09
#
EF% 58.7666.38 48.6568.96
# 45.9969.63
#
FS% 30.8664.46 24.7665.38
# 23.2865.08
#
HR, bpm 441.72660.38 423.60655.85 437.97660.14
LV: left ventricular; LVEDD: LV end-diastole diameter; LVESD: LV end-systole
diameter; LVEDV: LV end-diastolic volume; LVESV: LV end-systole volume;
LVPWD: LV posterior wall at end-diastole; LVPWS: LV posterior wall at end-
systole; LVAWD: LV anterior wall at end-diastole; LVAWS: LV anterior wall at
end-systole; EF%: percent ejection fraction; FS%: percent fractional shortening;
HR: heart rate.
*P,0.05 versus NTG mice;
{P,0.01 versus NTG mice;
#P,0.001 versus NTG mice.
doi:10.1371/journal.pone.0015167.t001
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E82K mutation induced apoptosis in the heart is likely mediated
by both of the FAS and mitochondrial pathways.
Discussion
Mutations in the LMNA gene are the most common cause of
familial dilated cardiomyopathy (FDC) showing to be the severity
of the cardiac symptoms, characterized by conduction defect,
arrhythmias, LV dysfunction, and dilation with heart failure or
sudden death [8–13]. A few mice models has been created for
lamin A/C knock out or mutations. The LMNA G608G
transgenic mice targeted the expression of the Hutchinson-Gilford
progeria syndrome (HGPS) mutation in keratin-5-expressing tissue
led to a typical phenotype of HGPS [16]. LMNA H222P mutated
gene knockin mice exhibited conduction defects, chamber dilation,
increased fibrosis and lack of hypertrophy, and also showed
muscular dystrophy and death at 4–9 months of age [17]. The
patients with heterozygous for the LMNA E82K mutation showed
clinical phenotypes of heart dilation and associated with
conduction system disease at their onset age of 32 or 33 years
[15]. The two Lmna
E82K transgenic mice lines exhibited chamber
dilation, increased heart weights, increased fibrosis, upregulation
of hypertrophic maker expression, nuclear structure defects and
conduction defects (Figures 1, 2, 3, Tables 1, 2), which was similar
with the phenotypes of the patients carrying the LMNA E82K
mutation.
The importance of BNP as a diagnostic and therapeutic
modality in cardiovascular disease is well known, it also acts as a
local regulator of ventricular remodeling and a modifier of cardiac
gene expression [18–20]. Acta1 is present in the developing heart
and it constitutes up to 20% of the striated actin of the adult heart.
Since Acta1 is a multifunctional protein that interacts with many
proteins involved in folding, polymerisation, contractility and
regulation of contractility, abnormal levels may affect any of those
functions [21]. In the normal adult heart, approximately 2 to 4%
of the myocardium is made up of collagen. The Col3a1 is one of
the essential components of the cardiovascular extracellular
Figure 2. The effects of LMNA E82K on heart dimensions and hypertrophic marker expression in the transgenic mice. (A) Heart
weight to body weight ratio was determined (n=14,
{ P,0.01 versus NTG mice). (B) Representative M-mode echocardiographic images of the LV
long-axis of the NTG and Lmna
E82K transgenic mice. (C) H&E staining patterns of the whole-heart longitudinal sections from 6 months old NTG and
Lmna
E82K transgenic mice (magnification 620). (D) Magnification of H&E stained sections of LV (magnification 6400). (E) Magnification of Masson
trichrome stained sections of LV in NTG and Lmna
E82K transgenic mice (magnification 6400). (F) Expression of Acta1, ANP, BNP and Col3a1 were
detected by western blot and RT-PCR procedure using GADPH as normalization.
doi:10.1371/journal.pone.0015167.g002
Table 2. ECG date for NTG and Lmna
82K transgenic mice at 7
months of age.
Parameters NTG
Lmna
E82K
(line 30)
Lmna
E82K
(line 35)
Number of mice 67 7
PR interval, ms 0.026960.0019 0.029860.0028 0.029060.0036
QRS duration, ms 0.011260.0014 0.012960.0028 0.013460.0017*
*P,0.05 versus NTG mice.
doi:10.1371/journal.pone.0015167.t002
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dium and thought to be responsible for abnormal myocardial
stiffness and for the impaired pumping capacity of the heart [22–
23]. The expression of BNP, Acta1 and Col3a1 was unregulated
in the two Lmna
E82K transgenic mice lines (Fig. 2F).
The death of the transgenic mice occurred from 3 months of age
and the mortality of the Lmna
E82K transgenic mice was about
15.8% at 10 months of age, while it showed that some patients
carrying this mutation died at the age of 42 and 48 years [15],
therefore the LMNA E82K mutation caused slight mortality in
transgenic mice compared with other mutations of LMNA as
LMNA H222P, LMNA M371K and LMNA N195K [17,24,25].
LMNA E82K mutation located in the coil 1B domain of central a-
helical rod domain of the lamin A and the lamin C proteins, those
were conserved regions of the rod domain which have been shown
to play crucial roles in the assembly of intermediate filament (IF)
dimers into higher order oligomers [26]. Mutations affect this
region of IF proteins and may disrupt the interaction between the
monomers and are linked to several diseases [27]. We observed
that the assembly of the Lamin A/C was disrupted (Fig. 3A), and
the integrity of the nuclear envelope was damaged (Fig. 3C) in the
Lmna
E82K transgenic mice. Members of the intermediate filament
superfamily are critical mechanical integrators of the nuclear
membrane and the cytoskeleton, protecting the cell from repeated
mechanical stress. Mutations in the lamin A/C gene may cause
cardiomyopathy by weakening nuclei, which increase the fragility
of nuclei and could be particularly harmful to muscle cells. Forces
generated during muscle contraction might potentially lead to
preferential breakage of nuclei containing a defective nuclear
lamina [14].
The accumulation of damaged nuclei as a result of a reduction
in load-bearing properties of the nuclear lamina might be a
possible mechanism of DCM [28,29]. The alternate possibility of
mechanism for the pathogenesis was the structural weakness of the
lamina, which might be a predisposing factor to induce nuclear
damage and apoptosis [28,29]. In the lamin A/C knockout mice,
the myocyte apoptosis was observed by 2-fold higher than that of
in NTG animals [30], but we found that the level of apoptosis was
8.5-fold higher in the Lmna
E82K transgenic mice than that of the
NTG mice (Fig. 4A and B). We concluded that LMNA E82K
mutation in mice, and probably in humans, disrupted integrity and
triggered apoptosis and finally resulted in DCM and heart failure.
It was possible that specialized properties of conduction system
myocytes made these more susceptible than surrounding myocytes
to pro-apoptotic signals triggered by mutated LMNA, and the
transgenic mice may developed the conduction defects [31]. Our
most interesting finding was that the expression of LMNA E82K
Figure 3. Morphological observation. (A) Immunodetection of
LMNA E82K in heart from NTG and Lmna
E82K transgenic mice at 6
months of age. Lamin A/C staining appeared red showing the
localization of LMNA protein and the sections were counterstained
blue with DAPI to visualize the nuclei. Scale bar =10 mm. (B) TEM
showed abnormal sarcomeres (white hollow arrow) and mitochondria
(white star) from LV free walls in the transgenic mice. Scale bars
=0.5mm. (C) The collapse and partial fragmentation in nuclear
membrane of myocytes in the Lmna
E82K transgenic mice were showed.
doi:10.1371/journal.pone.0015167.g003
Figure 4. TUNEL assay. (A) Photomicrographs of heart tissue used for
TUNEL assay, arrows indicate TUNEL-positive cells (magnification6800).
(B) The quantitative analysis of apoptotic cells in the heart of mice
(n=3,
{ P,0.01 versus NTG mice).
doi:10.1371/journal.pone.0015167.g004
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the activation of caspase-8 and caspase-3 in Lmna
E82K transgenic
mice (Fig. 5A–C). The release of cytochrome c from mitochondria
to cytosol was also induced by the expression of LMNA E82K,
followed the activation of caspase-9 (Fig. 6A–C).
FAS, as a member of the death receptor superfamily, plays a
central role in the death receptor pathway [32]. After FAS ligand
binding, FAS receptors undergo trimerization and recruit FAS-
associated death domain (FADD). FAS/FADD complex binds to
the initiator caspase-8. According to the cell type, activated
caspase-8 may propagate the apoptotic signal either through a
direct activation of executioner downstream caspases or via the
release of cytochrome c from mitochondria [33–36]. The
involvement of mitochondria in apoptotic processes has already
been clearly demonstrated [37,38], that the release of cytochrome
c triggers the assembly of Apoptotic protease-activating factor
(Apaf-1) and procaspase-9 to form an apoptosome, and procas-
pase-9 is then autolyticaly cleaved to active caspase-9, which then
activates procaspase-3 to active caspase resulting in cleavage of its
substrates and apoptosis [39,40].
Loss of myocytes is a feature of the cardiomyopathic process that
contributes to progressive decline in LV function and congestive
heartfailure [41,42].Althougha numberofstimuliappeartotrigger
theprocessofapoptosisincardiomyocyte.Ourresults indicatedthat
the two major signaling pathways of apoptosis: the death receptor
pathway and the mitochondrial pathway were activated by the
expression of LMNA E82K in heart tissue.
It has been indicated that lamin A/C regulates Wnt/b-catenin
and MAPK signal pathway, and it also regulates a certain
numbers of growth factors and transcription factors, like TGF-b
and c-Fos, which regulates differentiation, proliferation and
apoptosis in many cell types [43]. The LMNA mutations have
been shown to be the severity of the cardiac symptoms, which may
cause in diverse mechanisms. The apoptosis, at least for the
LMNA E82K or the mutations in the rod region of Lamin A/C,
might be an important mechanism causing continuous loss of
myocytes and lead to myocardial dysfunction. The genetic testing
of LMNA gene should be offered, because of the high risk of
sudden death in these patients. It could be needed for new
strategies to suppress and/or prevent inappropriate cardiac cell
death in patients carrying LMNA mutation as a therapeutic means
of slowing down the loss of myocytes.
Materials and Methods
Generation of the transgenic mice
The GRA substitution of LMNA cDNA (IMAGE: 2822703)
that results in the E82K mutation in the protein was induced using
the QuikChange site-directed mutagenesis kit (Stratagene, USA)
and the sequence was confirmed by DNA sequencing. The
mutated cDNA was cloned into an expression plasmid under the
a-MHC promoter. The transgenic mice were generated by
microinjection method [44]. Genotyping of transgenic mice was
facilitated by the polymerase chain reaction (PCR) using the
primers, 59 AGAAGGAGGGTGACCTGATAG and 59 AC-
CAGGTTGCTGTTCCTCT. The desired 490 bp fragment of
the transgenic gene was amplified for 35 cycles at condition of
94uC for 30 s, 57uC for 30 s and 72uC for 30 s. The expression of
Figure 5. Determination the expression of FAS and caspases. (A) The expression of FAS, caspase-8 and caspase-3 were measured by western
blot from the hearts of NTG and Lmna
E82K transgenic mice, and a representative experiment was shown. (B–C) The quantitative analysis of caspases
using GADPH as normalization (n=3,*P,0.05 versus NTG mice;
{ P,0.01 versus NTG mice;
#P,0.001 versus NTG mice).
doi:10.1371/journal.pone.0015167.g005
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antibody to human LMNA (Santa Cruz). All the mice were bred in
an AAALAC-accredited facility and the use of animals was
approved by the Animal Care and Use Committees of The
Institute of Laboratory Animal Science of Peking Union Medical
College (GC08-2001).
Light and electron microscopy
For light microscopy, cardiac tissue from mice at 6 months of
age was fixed in formaldehyde and mounted in paraffin blocks.
Sections were stained with Hematoxylin and Eosin (H&E) or
Masson trichrome. For electron microscopy, cardiac tissue was
routinely fixed in 2.5% glutaraldehyde in 0.1 M phosphate buffer
(pH 7.4) and postfixed in 1% osmium tetroxide buffer for 1 hr.
The sections were stained with uranyl acetate and lead citrate and
examined under a JEM-1230 transmission electron microscope.
Echocardiography
Mice were lightly anesthetized by intraperitoneal injection of
tribromoethanol at a dose of 18 ml/kg body weight. M-mode
echocardiography was performed at 2, 4, 6 and 8 months of age
for each transgenic mouse with a 30 MHz transducer (Vevo770,
Canada) [44,45].
Electrocardiography
Mice were fixed in the supine position on a heating pad to
maintain core body temperature, and limb leads were place
subcutaneously in accordance to chosen preferential derivation
(lead II). Traces were recorded using a digital system (ADInstru-
ments, USA) connected to a bioamplifier. The traces were
analyzed using the LabChart software package (ADInstruments,
USA) by an investigator who was blinded to the genotypes of the
mice.
Reverse transcription polymerase chain reaction (RT-PCR)
Total RNA was isolated from mice heart tissues using TRIzol
Reagent (Invitrogen). First-strand cDNA was synthesized accord-
ing to the Superscript III reverse transcriptase manufacturer’
protocol (Invitrogen). The expression level of mRNA for ANP,
BNP and Col3a1 was carried out by the RT-PCR and GAPDH
was used as normalization (For ANP, 59- ATGGGCTCC-
TTCTCCATCAC and 59- TTATCTTCGGTACCGGAAG-
CTG; For BNP, 59- ATGGATCTCCTGAAGGTGCTGTC
and 59- CTACAACAACTTCAGTGCGTTAC; for Col3a1, 59-
GGCAGTGATGGGCAACCT and 59- TCCCTTCGCACCG-
TTCTT; for GAPDH, 59- CAAGGTCATCCATGACAACT-
TTG and 59- GTCCACCACCCTGTTGCTGTAG).
Western blot
Total protein lysates from mice heart tissues were prepared by
homogenizing with lysis buffer (50 mM Tris, pH 7.4, 150 mM
NaCl, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS,
1 mM EDTA, and protease inhibitor cocktail). After performing
SDS-PAGE and transfer to nitrocellulose (Immobilon NC;
Millipore), the membranes were incubated overnight with
antibody to Lamin A/C (Santa Cruz); Acta1 (Abcam); FAS
(Santa Cruz); caspase-3 (Cell Signaling); caspase-8 (Cell Signaling)
or caspase-9 (Cell Signaling). After incubation with the appropri-
ate secondary antibody for 1 h at room temperature, antibody
binding was detected with a HRP-conjugated immunoglobulin G
Figure 6. Detection of cytochrome c release and activation of caspase-9. (A) Mitochondrial cytochrome c release and the expression of
caspase-9 were measured by western blot from the hearts of NTG and Lmna
E82K transgenic mice, and a representative experiment was shown. (B–C)
The quantitative analysis of cytochrome c and caspase-9 using GADPH as normalization (n=3,
#P,0.001 versus NTG mice).
doi:10.1371/journal.pone.0015167.g006
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nblotting luminal reagent, Santa Cruz). GAPDH was served as
normalization.
Immunofluorescence
The sections of hearts were prepared in a standard pathological
procedure. The sections were dewaxed, rehydrated, unmask the
epitope, blocked, then incubated with anti-lamin A/C monoclonal
Ab (Santa Cruz) overnight at 4uC Sections were washed with PBS
and incubated with DyLight-conjugated, affinity-purified anti-
mouse IgG (KPL) for 1 hr at room temperature, and all slides were
counterstained with 300 nM 4,6-diamidino-2-phenylindole
(DAPI, Invitrogen). After washing with PBS, sections were
mounted in ProLong Gold antifade reagent (Invitrogen). Images
of the sections were collected and analyzed under confocal laser
scanning microscopy (Leica TCS SP2, Germany).
TUNEL assay
TUNEL assay was performed in sections using an In Site Cell
Death Detection Kit (Roche Diagnostics GmbH, Mannheim,
Germany) principally according to the manufacturer’s instruc-
tions. The sections of heart tissues were incubated with the
TUNEL reaction mixture for 1 hr at 37uC in a dark, humidified
chamber. Labeled DNA was visualized with an anti-fluorescein
antibody conjugated with peroxidase (POD) using 3,39-diamino-
benzidine (DAB) as the chromogen. Sections were then washed,
counterstained with hematoxylin. For negative control, TdT was
omitted from the reaction mixture. Six images per heart (3 hearts
per genotype group) were acquired, and positive cells were
counted individually. Results were expressed as the percentage of
apoptotic cells among the total cell population.
Detection of mitochondrial cytochrome c release
A whole mouse heart from mice were excised and washed in
cold PBS and the cytosolic and mitochondria fractions were
derived following the Mitochondrial/Cytosol Fractionation Kit
manufacturer’s protocol (DBI Bioscience). The cytochrome c
content in cytosol and mitochondria was detected by western blot
analysis using antibody to cytochrome c (Cell Signaling). GAPDH
was served as normalization.
Statistical Analysis
Data was analyzed with unpaired two-tailed Student’s t-tests for
two groups, or one-way ANOVA for multiple groups followed by a
Tukey’s post hoc analysis. Data were expressed as mean 6 SEM
from individual experiments. Differences were considered as
significant at P,0.05.
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Table S1 Echocardiographic characteristics of WT and
Lmna
E82K transgenic mice at 2, 4 and 8 months of age.
LV: left ventricular; LVEDD: LV end-diastole diameter; LVESD:
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#P,0.001 versus NTG mice.
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